Global Blood Therapeutics (NASDAQ:GBT) Upgraded by BidaskClub to Sell

0
35
close up shotof water covering one hundered dollar bill

Global Blood Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Global Blood Therapeutics Upgraded by BidaskClub on 6/30/2020. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Strong Sell.

Shares of Global Blood Therapeutics traded up $0.94 on Monday, reaching $66.50. 0 shares of the stock traded hands, compared to its average volume of 946190. Shares of Global Blood Therapeutics ended Monday on at $66.50. The firm’s 50 day moving average is $70.47 and its 200 day moving average is $64.20.Global Blood Therapeutics  has a 12 month low of $64.94 and a 12 month high of $87.54. While on yearly highs and lows, Global Blood Therapeutics’s today has traded high as $68.03 and has touched $64.94 on the downward trend. See More Analyst Rating at: RATING

Global Blood Therapeutics Earnings and What to expect: 

Global Blood Therapeutics last issued its earnings results on May 6th, 2020. The reported ($1.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.27. The firm had revenue of $14.12 million for the quarter, compared to the consensus estimate of $3.65 million. Global Blood Therapeutics has generated ($4.71) earnings per share over the last year. Global Blood Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 5th, 2020 based off prior year’s report dates.

Earnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.49) to ($2.76) per share. The P/E ratio of Global Blood Therapeutics is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Global Blood Therapeutics is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Global Blood Therapeutics has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 4.20%
  • On 6/19/2020 Director Dawn Svoronos Sell 2,544 at average share price of $63.94 which equates to $162,663.36 in money value.
  • On 6/9/2020 CFO Jeffrey S Farrow Sell 15,208 at average price of  $67.00 with total value of : Not Data Available
  • On 5/26/2020 Insider Lesley Ann Calhoun Sell 2,700 at average price of  $70.10 with total value of : $189,270.00

Analyst at BidaskClub are also talking about :

  • 6/30/2020 – Winmark was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Vaxart was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – VSE was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Verisign was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Global Blood Therapeutics (NASDAQ:GBT) Moving Average Technical Analysis

5 day Moving Average is $65.86 And 5 day price change is -$0.13 (-0.20%)  with average volume for 5 day average is 2,130,600. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $65.57 and 20 day price change is -$2.17 (-3.16%) and average 20 day moving volume is 1,115,940. 50 day moving average is $70.47  and 50 day price change is -$4.05 ( -5.74%)  and with average volume for 50 days is : 978,276. 200 day moving average is $64.20  and 200 day price change is $12.19 (22.45%)  and with average volume for 200 days is : 1,003,833.

See More Analyst Rating at: RATING